Eutilex.Co.Ltd (263050) - Total Liabilities
Based on the latest financial reports, Eutilex.Co.Ltd (263050) has total liabilities worth ₩22.09 Billion KRW (≈ $14.97 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Eutilex.Co.Ltd growing its equity to track the company's year-over-year net asset growth rate.
Eutilex.Co.Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data.
Eutilex.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Eutilex.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yayla Enerji Uretim Turizm ve
IS:YAYLA
|
Turkey | TL86.14 Million |
|
Rossell India Limited
NSE:ROSSELLIND
|
India | Rs1.12 Billion |
|
Rex Industry Bhd
KLSE:9946
|
Malaysia | RM50.60 Million |
|
Conduril - Engenharia S.A
LS:CDU
|
Portugal | €157.89 Million |
|
Western Exploration Inc
V:WEX
|
Canada | CA$926.51K |
|
Lumens Co. Ltd
KQ:038060
|
Korea | ₩50.17 Billion |
|
Atech OEM
TWO:6109
|
Taiwan | NT$422.67 Million |
|
Pion Group AB Series B
ST:PION-B
|
Sweden | Skr327.60 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Eutilex.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 263050 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eutilex.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eutilex.Co.Ltd (2016–2024)
The table below shows the annual total liabilities of Eutilex.Co.Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩26.57 Billion ≈ $18.01 Million |
+116.66% |
| 2023-12-31 | ₩12.26 Billion ≈ $8.31 Million |
-26.62% |
| 2022-12-31 | ₩16.71 Billion ≈ $11.33 Million |
-63.11% |
| 2021-12-31 | ₩45.31 Billion ≈ $30.70 Million |
-3.64% |
| 2020-12-31 | ₩47.02 Billion ≈ $31.87 Million |
+256.70% |
| 2019-12-31 | ₩13.18 Billion ≈ $8.93 Million |
+74.17% |
| 2018-12-31 | ₩7.57 Billion ≈ $5.13 Million |
+2.88% |
| 2017-12-31 | ₩7.36 Billion ≈ $4.99 Million |
+29.42% |
| 2016-12-31 | ₩5.68 Billion ≈ $3.85 Million |
-- |
About Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more